Cardior Appoints Cardiac Disease and RNA Drug Development Experts to its Scientific Advisory Board Supporting Pipeline Expansion in Both Large and Orphan Cardiac Indications

Hanover, Germany, March 2, 2022 – Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the expansion of its Scientific Advisory Board (SAB) with four newly appointed cardiology and RNA drug development experts. Johann Bauersachs, MD; Perry Elliott, MD; Gerasimos Filippatos, MD, PhD; and Barry Ticho, MD, PhD, will provide Cardior with important scientific, medical and development guidance as the company advances its lead program CDR132L, an oligonucleotide-based ncRNA inhibitor targeting microRNA-132, towards a Phase 2 clinical trial in patients with heart failure. The SAB will also collaborate with Cardior’s leadership team as it further develops the breadth of its pipeline of ncRNA therapeutics with curative potential. Cardior’s innovative product candidates address the underlying causalities of heart diseases including genetic cardiomyopathies. David Crandall, PhD, member since inception of the SAB, will step down.